



---

Year: 2015

---

## **Adenosine attenuates human coronary artery smooth muscle cell proliferation by inhibiting multiple signaling pathways that converge on Cyclin D**

Dubey, Raghvendra K ; Fingerle, Jürgen ; Gillespie, Delbert G ; Mi, Zaichuan ; Rosselli, Marinella ; Imthurn, Bruno ; Jackson, Edwin K

**Abstract:** The goal of this study was to determine whether and how adenosine affects the proliferation of human coronary artery smooth muscle cells (HCASMCs). In HCASMCs, 2-chloroadenosine (stable adenosine analogue), but not N6-cyclopentyladenosine, CGS21680, or N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, inhibited HCASMC proliferation (A2B receptor profile). 2-Chloroadenosine increased cAMP, reduced phosphorylation (activation) of ERK and Akt (protein kinases known to increase cyclin D expression and activity, respectively), and reduced levels of cyclin D1 (cyclin that promotes cell-cycle progression in G1). Moreover, 2-chloroadenosine inhibited expression of S-phase kinase-associated protein-2 (Skp2; promotes proteolysis of p27Kip1) and upregulated levels of p27Kip1 (cell-cycle regulator that impairs cyclin D function). 2-Chloroadenosine also inhibited signaling downstream of cyclin D, including hyperphosphorylation of retinoblastoma protein and expression of cyclin A (S phase cyclin). Knockdown of A2B receptors prevented the effects of 2-chloroadenosine on ERK1/2, Akt, Skp2, p27Kip1, cyclin D1, cyclin A, and proliferation. Likewise, inhibition of adenylyl cyclase and protein kinase A abrogated 2-chloroadenosine's inhibitory effects on Skp2 and stimulatory effects on p27Kip1 and rescued HCASMCs from 2-chloroadenosine-mediated inhibition. Knockdown of p27Kip1 also reversed the inhibitory effects of 2-chloroadenosine on HCASMC proliferation. In vivo, peri-arterial (rat carotid artery) 2-chloroadenosine (20  $\mu$ mol/L for 7 days) downregulated vascular expression of Skp2, upregulated vascular expression of p27Kip1, and reduced neointima hyperplasia by 71% ( $P < 0.05$ ; neointimal thickness: control,  $37424 \pm 18371$  pixels; treated,  $10352 \pm 2824$  pixels). In conclusion, the adenosine/A2B receptor/cAMP/protein kinase A axis inhibits HCASMC proliferation by blocking multiple signaling pathways (ERK1/2, Akt, and Skp2) that converge at cyclin D, a key G1 cyclin that controls cell-cycle progression.

DOI: <https://doi.org/10.1161/HYPERTENSIONAHA.115.05912>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-120756>

Journal Article

Published Version

Originally published at:

Dubey, Raghvendra K; Fingerle, Jürgen; Gillespie, Delbert G; Mi, Zaichuan; Rosselli, Marinella; Imthurn, Bruno; Jackson, Edwin K (2015). Adenosine attenuates human coronary artery smooth muscle cell proliferation by inhibiting multiple signaling pathways that converge on Cyclin D. *Hypertension*, 2015(66):1207-1219.

DOI: <https://doi.org/10.1161/HYPERTENSIONAHA.115.05912>

## Adenosine Attenuates Human Coronary Artery Smooth Muscle Cell Proliferation by Inhibiting Multiple Signaling Pathways That Converge on Cyclin D

Raghvendra K. Dubey, Jürgen Fingerle, Delbert G. Gillespie, Zaichuan Mi, Marinella Rosselli, Bruno Imthurn, Edwin K. Jackson

**Abstract**—The goal of this study was to determine whether and how adenosine affects the proliferation of human coronary artery smooth muscle cells (HCASMCs). In HCASMCs, 2-chloroadenosine (stable adenosine analogue), but not N<sup>6</sup>-cyclopentyladenosine, CGS21680, or N<sup>6</sup>-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, inhibited HCASMC proliferation (A<sub>2B</sub> receptor profile). 2-Chloroadenosine increased cAMP, reduced phosphorylation (activation) of ERK and Akt (protein kinases known to increase cyclin D expression and activity, respectively), and reduced levels of cyclin D1 (cyclin that promotes cell-cycle progression in G1). Moreover, 2-chloroadenosine inhibited expression of S-phase kinase-associated protein-2 (Skp2; promotes proteolysis of p27<sup>Kip1</sup>) and upregulated levels of p27<sup>Kip1</sup> (cell-cycle regulator that impairs cyclin D function). 2-Chloroadenosine also inhibited signaling downstream of cyclin D, including hyperphosphorylation of retinoblastoma protein and expression of cyclin A (S phase cyclin). Knockdown of A<sub>2B</sub> receptors prevented the effects of 2-chloroadenosine on ERK1/2, Akt, Skp2, p27<sup>Kip1</sup>, cyclin D1, cyclin A, and proliferation. Likewise, inhibition of adenylyl cyclase and protein kinase A abrogated 2-chloroadenosine's inhibitory effects on Skp2 and stimulatory effects on p27<sup>Kip1</sup> and rescued HCASMCs from 2-chloroadenosine-mediated inhibition. Knockdown of p27<sup>Kip1</sup> also reversed the inhibitory effects of 2-chloroadenosine on HCASMC proliferation. In vivo, peri-arterial (rat carotid artery) 2-chloroadenosine (20 μmol/L for 7 days) downregulated vascular expression of Skp2, upregulated vascular expression of p27<sup>Kip1</sup>, and reduced neointima hyperplasia by 71% (*P*<0.05; neointimal thickness: control, 37424±18371 pixels; treated, 10352±2824 pixels). In conclusion, the adenosine/A<sub>2B</sub> receptor/cAMP/protein kinase A axis inhibits HCASMC proliferation by blocking multiple signaling pathways (ERK1/2, Akt, and Skp2) that converge at cyclin D, a key G1 cyclin that controls cell-cycle progression. (*Hypertension*. 2015;66:1207-1219. DOI: 10.1161/HYPERTENSIONAHA.115.05912.) • [Online Data Supplement](#)

**Key Words:** adenosine ■ A<sub>2B</sub> receptor ■ cyclin D1 ■ p27<sup>Kip1</sup> ■ Skp2 ■ vascular smooth muscle cells

Excessive proliferation of some cell types (eg, vascular smooth muscle cells [VSMCs], glomerular mesangial cells [cells phenotypically similar to VSMCs], and cardiac fibroblasts) and deficient proliferation of other cell types (eg, vascular endothelial cells and renal epithelial cells) can trigger hypertension-induced pathological vascular, cardiac, and renal remodeling, leading to cardiovascular and renal diseases.<sup>1</sup> Thus, endogenous factors that inhibit proliferation of VSMCs, glomerular mesangial cells, and cardiac fibroblasts and that stimulate the proliferation of vascular endothelial cells and renal epithelial cells may provide protection against cardiovascular and renal diseases. Adenosine seems to be one such

factor. Adenosine potently inhibits the proliferation of rat renal preglomerular VSMCs,<sup>2,3</sup> rat<sup>4-8</sup> and human<sup>9</sup> aortic VSMCs, rat<sup>3,10</sup> and human<sup>11</sup> glomerular mesangial cells, and rat cardiac fibroblasts<sup>12-16</sup>; yet, adenosine stimulates the proliferation of rat aortic,<sup>17</sup> rat renal microvascular,<sup>18</sup> and porcine coronary<sup>17</sup> vascular endothelial cells, as well as human<sup>18</sup> renal epithelial cells. In addition, adenosine has several other desirable tissue-protecting actions, such as promoting neovascularization<sup>19-21</sup> and preventing and reducing inflammation and hypoxia.<sup>22-27</sup> Thus, adenosine per se, adenosine receptor agonists, or adenosine-modulating drugs (ie, the broad class of adenosinergic drugs) may be useful for preventing and treating several cardiovascular

Received May 26, 2015; first decision June 5, 2015; revision accepted September 7, 2015.

From the Department of Reproductive Endocrinology, University Hospital Zurich, Switzerland (R.K.D., M.R., B.I.); Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland (R.K.D.); Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine (D.G.G., Z.M., E.K.J.); and Preclinical Pharma Research 68/209, F. Hoffmann-La-Roche, Basel, Switzerland (J.F.).

Current address for J.F.: Natural and Medical Sciences Institute at the University of Tübingen, Markwiesenstr. 55, D-72770 Reutlingen, Germany.

Presented in part at the American Heart Association Council for HBPR Research Meeting, Chicago, IL, September 23–26, 2009, and published in abstract form.

**The online-only Data Supplement is available with this article at <http://hyper.ahajournals.org/lookup/suppl/doi:10.1161/HYPERTENSIONAHA.115.05912/-/DC1>.**

Correspondence to Raghvendra K. Dubey, Department of Reproductive Endocrinology, University Hospital Zurich, Areal Wagi Schlieren, Wagistrasse 14, Schlieren 8952, Switzerland. E-mail Raghvendra.dubey@usz.ch

© 2015 American Heart Association, Inc.

*Hypertension* is available at <http://hyper.ahajournals.org>

DOI: 10.1161/HYPERTENSIONAHA.115.05912

and renal diseases induced by hypertension, particularly those associated with excessive proliferation of VSMCs. However, whether adenosine inhibits human coronary artery smooth muscle cell (HCASMC) proliferation is unclear, and one objective of the current study was to determine the effects of adenosine on this critically important cell type.

Although adenosine is well known to inhibit proliferation of some types of VSMCs, the underlying mechanism by which adenosine inhibits mitogen-induced cell proliferation is unknown. There is increasing evidence that mitogens promote cell proliferation by engaging ERK1/2 and Akt signaling pathways that converge at cyclin D (Figure 1), a G1 phase cyclin with 3 isoforms (D1, D2, and D3, with D1 being the most widely expressed). ERK1/2 phosphorylates transcription factors that increase the expression of cyclin D<sup>28</sup>, whereas Akt increases the activity of cyclin D via phosphorylating ezrin–radixin–moesin-binding phosphoprotein 50. In this regard, ezrin–radixin–moesin-binding phosphoprotein 50 stabilizes S-phase kinase-associated protein-2 (Skp2) and optimizes its cellular location.<sup>29</sup> Skp2 promotes the polyubiquitination of p27<sup>Kip1</sup> and thus accelerates p27<sup>Kip1</sup> degradation,<sup>30</sup> thereby decreasing levels of p27<sup>Kip1</sup>. Normally, p27<sup>Kip1</sup> binds to complexes of cyclins with their respective cyclin-dependent kinases (Cdk), thus preventing cyclin–Cdk complexes from phosphorylating their substrates.<sup>31</sup> Importantly, p27<sup>Kip1</sup> impairs the function of cyclin D–Cdk4/6 complexes<sup>31</sup> that are primarily responsible for promoting cell-cycle progression in G1 phase of the cell cycle.<sup>32,33</sup> Therefore, a reduction of p27<sup>Kip1</sup> augments cyclin D activity. Cyclin D promotes, via activation of Cdk4/6, hyperphosphorylation of retinoblastoma protein (Rb), causing Rb to release the protein elongation 2 factor.<sup>34</sup> Elongation 2 factor then serves as a transcription factor to increase the expression of genes for G1/S and S phase cyclins,<sup>34</sup> thus driving the cell cycle through S and G2 phases and finally mitosis and cytokinesis (Figure 1).

How could adenosine interfere with mitogen-induced cell proliferation? Accumulating evidence suggests that in some cell types, adenosine mediates antiproliferative effects via A<sub>2B</sub> receptors.<sup>7,9,35,36</sup> Stimulation of A<sub>2B</sub> receptors activates adenylyl cyclase, resulting in increased cAMP production,<sup>37</sup> and studies by Wu et al demonstrate that cAMP, via protein kinase A (PKA), may downregulate the expression of Skp2,<sup>38,39</sup> which in turn increases the levels of p27<sup>Kip1</sup>. In addition, PKA can interfere with signaling cascades that phosphorylate (activate) ERK1/2<sup>40,41</sup> and Akt,<sup>42</sup> thus providing additional mechanisms for inhibiting cyclin D signaling. Together, this information suggests the hypothesis shown in Figure 1 that adenosine could inhibit HCASMC proliferation by engaging the A<sub>2B</sub> receptor/adenylyl cyclase/cAMP/PKA pathway, which is followed by PKA-mediated inhibition of multiple signaling pathways that converge at cyclin D. The net result is the reduced expression and function of cyclin D, which arrests cells in G1. Another goal of the present study was to test this hypothesis.

## Methods

### Materials

Adenosine, 2-chloroadenosine (stable adenosine analogue), and erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; increases endogenous

adenosine by inhibiting adenosine deaminase and thus reducing the metabolism of adenosine to inosine) were purchased from Sigma-Aldrich (St. Louis, MO). N<sup>6</sup>-cyclopentyladenosine (CPA; selective A<sub>1</sub> receptor agonist), CGS21680 (selective A<sub>2A</sub> receptor agonist), 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; selective A<sub>1</sub> receptor antagonist), 5-iodotubercidin (IDO; increases endogenous adenosine by inhibiting adenosine kinase and thus reducing the metabolism of adenosine to 5'-AMP), 5'-N-ethylcarboxamidoadenosine (NECA; nonselective adenosine receptor agonist), 5'-N-methylcarboxamidoadenosine (MECA; nonselective adenosine receptor agonist), 1-deoxy-1-[6-[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-β-D-ribofuranuronamide (IB-MECA; selective A<sub>3</sub> receptor agonist), SCH442416 (selective A<sub>2A</sub> receptor antagonist), MRS1754 (selective A<sub>2B</sub> receptor antagonist), and VUF5574 (selective A<sub>3</sub> receptor antagonist) were purchased from Tocris (Minneapolis, MN). <sup>3</sup>H-thymidine (specific activity, 11.8 Ci/mmol) was purchased from PerkinElmer NEN (Waltham, MA). All other reagents were of tissue culture or best grade available.

### Cell Cultures

HCASMCs from 3 donors were procured from GIBCO (Life Technologies, CA) and LONZA (Walkersville, MD). The cells were precharacterized for smooth muscle cell-specific markers and for their compatible (<5% variation) growth response to fetal calf serum (FCS; 2.5%). Cells were cultured in M231 culture medium containing smooth muscle growth supplement (Life Technologies, CA) and under standard tissue culture conditions as described previously.<sup>43</sup> HCASMCs in third to fifth passage were used for the growth and molecular assays.

### <sup>3</sup>H-Thymidine Incorporation

To assess DNA synthesis by HCASMCs, we used <sup>3</sup>H-thymidine incorporation as described previously.<sup>43</sup> HCASMCs grown to subconfluence and serum-starved for 24 hours were treated for 48 hours with 2.5% FCS in medium with or without test agents. Four hours before the termination of the experiment, cells were pulsed with <sup>3</sup>H-thymidine, and the incorporation of <sup>3</sup>H-thymidine into the DNA was analyzed by measuring radioactivity in the acid-insoluble fraction using a β-scintillation counter.

### Cell Number

After serum starvation, cultures were treated with 2.5% FCS with or without test agents. After 4 days, cells were dislodged by trypsinization and counted in a Coulter Counter.

### Cell Cycle Analysis

HCASMCs at 60% confluence were serum-starved for 24 hours and then grown in 2.5% FCS for 3 days. Cells were stained with propidium iodide, and DNA content was analyzed by flow cytometry.

### Cell Migration Studies

2.5% FCS-induced HCASMC migration was assessed using the modified Boydens chamber and as previously described in detail by us.<sup>43</sup>

### Assays for Intracellular Mechanisms

Changes in the phosphorylation state of signal transduction proteins and changes in the expression of cell cycle regulatory proteins were analyzed by Western blotting as previously described.<sup>44</sup> Briefly, cells were grown and treated in 60 mm culture dishes and were washed once with PBS and then lysed in 70 μL of lysis buffer (Cell Signaling Technology, Beverly, MA). The samples were sonicated, and the protein concentration was measured using a BCA protein assay kit (Pierce, Rockford, IL). Proteins were denatured by boiling the samples at 95°C for 5 minutes. Equal amounts of protein (10–20 μg/lane) were diluted in 5× loading buffer (Fermentas, Hanover, MD) plus 0.1 mol/L dithiothreitol and 2.5% 2-mercaptoethanol, and proteins were resolved using a 10% sodium dodecyl sulfate–polyacrylamide gel and then transferred to a nitrocellulose membrane. Subsequently, for

specific protein expression, the membranes were blocked in 5% non-fat dry milk in PBS/0.2% Tween 20 (overnight at 4°C) and incubated with the primary antibody for specific times at room temperature or 4°C (Table S1 in the online-only Data Supplement). Primary antibodies (Table S1) were diluted in washing buffer (1% nonfat dry milk in PBS/0.2% Tween 20) and were specific for the proteins investigated and had cross-reactivity for both human and rat proteins. Following incubation with the primary antibodies, the membranes were incubated for 1 hour with the second antibody (goat anti-mouse IgG-peroxidase conjugated [Pierce 31430, diluted 1:25000] or goat anti-rabbit IgG-peroxidase conjugated [Pierce 31460, diluted 1:25000]). Peroxidase activity was detected using ECL (Pierce), and the membranes were exposed to Hyperfilm ECL (Amersham, Dübendorf, CH).

### A<sub>2B</sub> and p27 Silencing Studies

Smart pool on target plus siRNA kit from Dharmacon was used according to the instructions to silence CDKN1B (p27<sup>Kip1</sup>) or


ADORA2B (human A<sub>2B</sub> adenosine receptors) in HCASMCs. Control smart pool siRNA from Dharmacon was used as control.

### cAMP Levels

Extracellular (supernatant) and intracellular (cellular fraction) cAMPs were pooled, and total cAMP levels were analyzed by high-performance liquid chromatography using our previously described method.<sup>9</sup>

### Carotid Artery Injury Studies

Balloon injury-induced neointima formation was assessed in animals (male Wistar-Kyoto rats; 350–400 g; Harlan, Fullinsdorf, Switzerland), as described previously.<sup>45,46</sup> Briefly, animals were anesthetized with ketamine plus xylazine (intraperitoneal injection). To induce arterial injury, the left common carotid artery was exposed at the bifurcation, and a 2F Fogarty embolectomy catheter was inserted. The inflated balloon was pulled through the common carotid artery 3× to completely denude the endothelium, and the external carotid artery was permanently ligated. 2-Chloroadenosine (20 μmol/L) was added to 25% (wt/vol) pluronic gel solution (F127, BASF Corp, Parsippany, NJ) and kept in nongelled form at 4°C. The neck muscles adjacent to the carotid artery were separated to expose the artery and to provide a space for the gel by lifting the artery slightly from the muscle with forceps. The liquid solution (100 μL) was then topically applied with an Eppendorf pipet on the exposed carotid artery. At 37°C, the solution rapidly gelled, and the vessel was thus covered by a translucent layer enveloping the treated area (~1 cm length of artery). Because no muscles were cut, all tissues returned to their original position, and the carotid artery was covered again by muscle. The skin was subsequently sutured into place with 3 to 4 stitches of silk suture. After 7 days, the animals were euthanized and perfusion-fixed for morphometric analysis. To assess the impact of 2-chloroadenosine on proliferation of intimal carotid artery VSMCs after balloon injury, animals (placebo n=7, treated n=7) receiving the vehicle or 2-chloroadenosine were euthanized and perfusion-fixed 7 days after balloon injury and sections immunostained for Ki67 to assess proliferating carotid artery VSMCs. The 7-day period was selected because it is well documented that the proliferative activity of carotid artery VSMCs peaks at day 7 after injury.<sup>47,48</sup> To assess whether 2-chloroadenosine affects expression of Skp2 and p27<sup>Kip1</sup> in vivo, rats (placebo n=5 and treated n=5) were euthanized on day 8 and the carotid arteries snap-frozen in liquid nitrogen. Subsequently, segments from placebo or 2-chloroadenosine-treated animals were homogenized and lysed, and proteins of interest were analyzed using Western blotting.



**Figure 1.** Signaling schematic depicting our hypothesis of how adenosine regulates human coronary artery smooth muscle cell cell-cycle progression. Extracellular mitogens activate classical signal transduction pathways that ultimately phosphorylate (and thus activate) ERK1/2 and Akt. ERK1/2 is well known to increase expression of cyclin D (G1 phase cyclin). Phosphorylated Akt activates a signal transduction pathway that stabilizes S-phase kinase-associated protein-2 (Skp2), which is the F-box protein of SCF<sup>Skp2</sup> ubiquitin ligase that polyubiquitinates p27<sup>Kip1</sup> and thus accelerates the degradation of p27<sup>Kip1</sup>. Removal of p27<sup>Kip1</sup> de-inhibits cyclin D activity. Cyclin D activates cyclin-dependent kinases 4 and 6 to hyper-phosphorylate retinoblastoma protein (Rb), thus releasing the transcription factor elongation 2 factor (E2F) and allowing increased expression of G1/S and S phase cyclins. G1/S and S phase cyclins then drive the cell cycle forward to complete mitogenesis and cytokinesis (cell proliferation). Adenosine stimulates A<sub>2B</sub> receptors that are positively coupled to adenylyl cyclase, which increases the formation cAMP and activates protein kinase A. Protein kinase A decreases expression of Skp2 and inhibits phosphorylation of Akt, resulting in increased levels of p27<sup>Kip1</sup> which reduce cyclin D activity. Protein kinase A also inhibits phosphorylation of ERK1/2, which reduces cyclin D expression. This protein kinase A (PKA)-induced signaling converges at cyclin D. This results in inhibition of Rb hyperphosphorylation, and hypophosphorylated Rb can now bind E2F and prevent this transcription factor from increasing the expression of G1/S and S phase cyclins.


### Statistics

Treatment effects on cross-sectional areas were analyzed by using analysis of variance or the nonparametric Kruskal–Wallis test. Expression and growth data were analyzed using analysis of variance, and statistical significance ( $P < 0.05$ ) was calculated using Fisher's least significant difference test. All growth experiments were performed in triplicates or quadruplicates using 3 separate HCASMC cultures. For Western blotting experiments, each treatment was conducted in triplicate or quadruplicates and with 3 separate HCASMC cultures. The densitometric analysis of protein expression is presented as a ratio against the appropriate control (phosphorylated ERK1/2 to ERK1/2; phosphorylated Akt to Akt; cyclin D1 to β-actin; cyclin A to β-actin; p27<sup>Kip1</sup> to β-actin; Skp2 to β-actin).

### Results

Because the expression profile of adenosine receptor subtypes may determine the overall pharmacology of adenosine, we first probed for the presence of adenosine receptor subtypes in the HCASMCs used in the present study. cDNA size fractionation showed strong expression of mRNA for A<sub>1</sub> and A<sub>2B</sub> receptors, but only weak mRNA expression for A<sub>2A</sub> and A<sub>3</sub> receptors (Figure 2A). Likewise, Western blotting detected strong bands for A<sub>1</sub> and A<sub>2B</sub> receptors, a faint band for A<sub>2A</sub>






**Figure 2.** Adenosine  $A_{2B}$  receptor mediated inhibition of human coronary artery smooth muscle cell growth. **A**, Representative northern blots (upper) and western blots (lower) showing the presence of  $A_1$  and  $A_{2B}$  receptors, with low expression of  $A_{2A}$  receptors and minimal expression of  $A_3$  receptors. **B**, Concentration–response relationships for the inhibition of  $^3H$ -thymidine incorporation (DNA synthesis) by 2-chloroadenosine (CI-Ad), 5'-N-methylcarboxamidoadenosine (MECA), 1-deoxy-1-[6-[[[3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-β-D-ribofuranuronamide (IB-MECA), 5'-N-ethylcarboxamidoadenosine (NECA), N<sup>6</sup>-cyclopentyladenosine (CPA), and CGS21680 (CGS). **C**, The effects of CI-Ad (1 μmol/L) on DNA synthesis in the presence and absence of 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; selective  $A_1$  antagonist, 100 nmol/L); SCH442416 (SCH; selective  $A_{2A}$  antagonist, 100 nmol/L); and MRS1754 (MRS; selective  $A_{2B}$  antagonist, 100 nmol/L). **D**, The inhibitory effects of CI-Ad (100 nmol/L) on cell-cycle distribution. \* $P < 0.05$  vs no treatment; § $P < 0.05$  significant reversal of CI-Ad effects. Values represent mean ± SEM from 3 separate experiments, each conducted in triplicates or quadruplicates.


receptors, and no signal for  $A_3$  receptors (Figure 2A). These findings suggest that  $A_1$  or  $A_{2B}$  receptors would likely dominate the pharmacology of adenosine in these HCASMCs.

Treatment of HCASMCs with 2-chloroadenosine (stable adenosine analogue) concentration-dependently attenuated DNA synthesis (Figure 2B). Using various pharmacological



**Figure 3.** **A**, Bar graphs show the effects of 2-chloroadenosine (CI-Ad; 1 μmol/L) and 5'-N-methylcarboxamidoadenosine (MECA; 1 μmol/L) on cell number in human coronary artery smooth muscle cells (HCASMCs). The inhibitory effects of CI-Ad were reversed by MRS1754 (MRS;  $A_{2B}$  receptor antagonist), but not by SCH442416 (SCH;  $A_{2A}$  receptor antagonist), 8-cyclopentyl-1,3-dipropylxanthine (DPCPX;  $A_1$  antagonist), or VUF5574 (VUF;  $A_3$  antagonist). Similar to CI-Ad, the effects of MECA were blocked by MRS1754. \* $P < 0.05$  vs control; §significant reversal of the inhibitory effects. **B**, Bar graph demonstrates the effects of CI-Ad (1 μmol/L) and MECA (1 μmol/L) on cell migration in HCASMCs. The inhibitory effects of CI-Ad were mimicked by MECA, but not by N<sup>6</sup>-cyclopentyladenosine (CPA;  $A_1$  agonist), CGS21680 (CGS;  $A_{2A}$  agonist), or 1-deoxy-1-[6-[[[3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-β-D-ribofuranuronamide (IB-MECA; IB-M:  $A_3$  adenosine receptor agonist). Moreover, the effects of CI-Ad and MECA were reversed by MRS1754 (MRS;  $A_{2B}$  receptor antagonist). \* $P < 0.05$  vs control; §significant reversal of the inhibitory effects. **C**, Effects of erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; 5 μmol/L; adenosine deaminase inhibitor) and 5-iodotubercidin (IDO; 0.1 μmol/L; adenosine kinase inhibitor) on cell number in HCASMCs. The inhibitory effects were significantly enhanced when the adenosine catabolism inhibitors EHNA+IDO were combined. Moreover, the effects of EHNA+IDO were reversed by MRS1754 (MRS;  $A_{2B}$  receptor antagonist), but not by SCH442416 (SCH;  $A_{2A}$  receptor antagonist), DPCPX ( $A_1$  antagonist), or VUF5574 (VUF;  $A_3$  antagonist), suggesting that endogenous adenosine inhibits HCASMC growth via  $A_{2B}$  receptors. \* $P < 0.05$  vs control; §significant reversal of the inhibitory effects. Values represent mean ± SEM from 3 separate experiments, each conducted in triplicates or quadruplicates.

agents (adenosine receptor subtype selective and nonselective agonists and antagonists), we further assessed the role of all adenosine receptor subtypes ( $A_1$ ,  $A_{2A}$ ,  $A_{2B}$ , and  $A_3$ ) in mediating the anti-mitogenic effects in HCASMCs. The highest (1 μmol/L) concentrations of CPA ( $A_1$  receptor-selective agonist), CGS21680 ( $A_{2A}$  receptor-selective agonist), and IB-MECA ( $A_3$  receptor-selective agonist) failed to inhibit DNA synthesis (Figure 2B). MECA was slightly more potent than NECA (both are nonselective adenosine receptor agonists; Figure 2B). MRS1754 ( $A_{2B}$  receptor-selective antagonist), but not DPCPX ( $A_1$  receptor-selective antagonist), SCH442416 ( $A_{2A}$  receptor-selective antagonist), or VUF5574 ( $A_3$  receptor-selective antagonist), blocked the



**Figure 4.** Western blots show effects of 0.5  $\mu\text{mol/L}$  of 2-chloroadenosine (Cl-Ad), 5'-*N*-methylcarboxamidoadenosine (MECA), *N*<sup>6</sup>-cyclopentyladenosine (CPA), CGS21680 (CGS), 1-deoxy-1-[6-[[[3-iodophenyl)methyl]amino]-9H-purin-9-yl]-*N*-methyl- $\beta$ -D-ribofuranuronamide (IB-MECA; IB-M), Cl-Ad+MRS1754 (MRS; 100 nmol/L), or MECA+MRS1754 on levels of hyperphosphorylated retinoblastoma protein (pRb), phosphorylated ERK1/2 (ERK1/2-P), total ERK1/2, phosphorylated Akt (Akt-P), total Akt, cyclin D1, cyclin A, p27<sup>Kip1</sup> (p27), and S-phase kinase-associated protein-2 (Skp2) expression in human coronary artery smooth muscle cells (HCASMCs). Sub-confluent monolayers of HCASMCs growth arrested for 36 hours in 0.4% BSA were treated and stimulated with 2.5% fetal calf serum (FCS) for 48 hours. Cell lysates were subsequently analyzed by western blotting. The densitometric analysis of all the protein expression is presented as a ratio against the appropriate control (phosphorylated ERK1/2 to ERK1/2; phosphorylated Akt to Akt; cyclin D1 to  $\beta$ -actin; cyclin A to  $\beta$ -actin; p27<sup>Kip1</sup> to  $\beta$ -actin; Skp2 to  $\beta$ -actin). \* $P < 0.05$  versus control; §significant reversal of the inhibitory effects. Values represent mean  $\pm$  SEM from 3 separate experiments, each conducted in triplicates or quadruplicates.

effects of 2-chloroadenosine on DNA synthesis (all antagonists at 100 nmol/L; Figure 2C). Moreover, the inhibitory effects of 2-chloroadenosine on cell number were reversed by MRS1754, but not by DPCPX, SCH442416, or VUF5574 (Figure 3A). Similar to 2-chloroadenosine, the inhibitory effects of MECA on cell number were antagonized by MRS1754 (Figure 3A). Treatment with 2-chloroadenosine and MECA, but not CPA, CGS21680, or IB-MECA, inhibited HCASMC migration, and the inhibitory effects of 2-chloroadenosine and MECA on cell migration were blocked by MRS1754 (Figure 3B). EHNA (blocks adenosine deaminase) and IDO (blocks adenosine kinase), administered separately, inhibited cell proliferation, and these effects were enhanced in cells treated with EHNA plus IDO (Figure 3C). MRS1754, but not DPCPX, SCH442416, or VUF5574, abrogated the inhibitory effects of EHNA plus IDO on cell proliferation (Figure 3C, right panel). Cell cycle distribution experiments using flow cytometry demonstrated that 2-chloroadenosine increased the percentage of cells in G0/G1 while reducing the percentage of cells in S phase and G2/M phase (Figure 2D). Trypan blue exclusion tests demonstrated that none of the aforementioned treatments altered cell viability. These findings indicate that in HCASMCs, A<sub>2B</sub> receptors dominate the


pharmacology of adenosine, leading to inhibition of cell proliferation, DNA synthesis, and cell migration and arrest of cells in the G0/G1 phase of the cell cycle.

Treatment of HCASMCs with 2-chloroadenosine inhibited hyperphosphorylation of Rb and phosphorylation of ERK1/2 and Akt (Figure 4). Moreover, treatment with 2-chloroadenosine decreased levels of Skp2 (F-box protein of SCF<sup>Skp2</sup> ubiquitin ligase responsible for polyubiquitination of and subsequent proteolysis of p27<sup>Kip1</sup>) and upregulated levels of p27<sup>Kip1</sup> (p27<sup>Kip1</sup> inhibits cell cycle progression by blocking function of cyclins). These effects were accompanied by inhibition of cyclin A and cyclin D1 expression (Figure 4). The modulatory effects of 2-chloroadenosine on signal transduction proteins were mimicked by MECA, but not by CPA, CGS21680, or IB-MECA (Figure 4). The modulatory effects of 2-chloroadenosine and MECA on signal transduction pathways were blocked by MRS1754 (Figure 4), implying a role for A<sub>2B</sub> receptors in mediating the inhibitory effects of adenosine on cell cycle progression in HCASMCs.

Western blotting confirmed that treatment with siRNA silenced the expression of A<sub>2B</sub> receptors (Figure 5A). At the functional level, 2-chloroadenosine increased cAMP production in control cells and cells treated with negative-control siRNA, but not in cells treated with A<sub>2B</sub> receptor siRNA (Figure 5A). 2-Chloroadenosine inhibited DNA synthesis in HCASMCs treated with negative-control siRNA but not in cells treated with A<sub>2B</sub> siRNA (Figure 5B). Also the inhibitory effects of MECA, NECA, and EHNA+IDO were blocked by A<sub>2B</sub> siRNA (Figure 5B). Downregulation of A<sub>2B</sub> receptors by siRNA did not abrogate the inhibitory effects of 8-bromo-cAMP on DNA synthesis (Figure 5B). These results further support the conclusion that A<sub>2B</sub> receptors mediate the anti-mitogenic effects of adenosine.

In HCASMCs in which A<sub>2B</sub> receptors were silenced, treatment with 2-chloroadenosine failed to abrogate phosphorylation of key signal transduction proteins (pRb, ERK1/2, and Akt) associated with cell proliferation (Figure 6). The inhibitory effects of 2-chloroadenosine on cell cycle regulatory proteins cyclin A and cyclin D1 were also abrogated in HCASMCs with silenced A<sub>2B</sub> receptors. Additionally, the inhibitory effects of 2-chloroadenosine on Skp2 and stimulatory effects on p27<sup>Kip1</sup> were lost in HCASMCs lacking A<sub>2B</sub> receptors (Figure 6).


cAMP may inhibit HCASMC proliferation via Skp2 downregulation and p27<sup>Kip1</sup> upregulation.<sup>38</sup> Because 2-chloroadenosine-stimulated cAMP production was inhibited in HCASMCs with silenced A<sub>2B</sub> receptors, we further elucidated the role of this pathway in mediating the inhibitory effects of 2-chloroadenosine on cell proliferation. Treatment of HCASMCs with 2-chloroadenosine concentration-dependently decreased Skp2 and increased p27<sup>Kip1</sup> expression (Figure 7A). The stimulatory effects of 2-chloroadenosine on p27<sup>Kip1</sup> expression in HCASMCs was abolished in cells in which adenosine A<sub>2B</sub> receptors were silenced with siRNA (Figure 7B). Moreover, the inhibitory effects of 2-chloroadenosine on DNA synthesis were abrogated in HCASMCs in which adenosine A<sub>2B</sub> receptors were silenced (Figure 7B). The observations that the stimulatory effects of 2-chloroadenosine on p27<sup>Kip1</sup> and inhibitory effects on DNA synthesis are abolished in HCASMCs lacking adenosine A<sub>2B</sub> receptors suggest a role



**Figure 5.** **A** (Top), Western blot depicting the downregulation of the expression of A<sub>2B</sub> receptors in human coronary artery smooth muscle cells (HCASMCs) by siRNA against A<sub>2B</sub> receptors. No treatment with siRNA (Con); treated with negative-control siRNA (si-Con); treated with siRNA against A<sub>2B</sub> receptor (siRNA). Bar graph for the western blot represents change in optical density ratio of A<sub>2B</sub> to β-actin. **(Bottom)**, Depicts the effects of siRNA against A<sub>2B</sub> receptors on the stimulatory effects of 2-chloroadenosine (CI-Ad; 1 μmol/L) on cAMP levels in HCASMCs. No treatment with siRNA (Control); treated with negative-control siRNA (siControl); treated with siRNA against A<sub>2B</sub> receptor (siRNA). \*P < 0.05 vs no CI-Ad. **B**, Inhibitory effects of CI-Ad, 5'-N-methylcarboxamidoadenosine (MECA), 5'-N-ethylcarboxamidoadenosine (NECA), N<sup>6</sup>-cyclopentyladenosine (CPA), 8-bromo-cAMP (cAMP), and erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; 10 μmol/L) plus 5-iodotubercidin (IDO; 0.1 μmol/L) on DNA synthesis in the absence and presence of A<sub>2B</sub> receptor siRNA in HCASMCs. No treatment with agonists (Control); treated with negative-control siRNA (si-Control); treated with siRNA against A<sub>2B</sub> receptor (A<sub>2B</sub>-siRNA). \*P < 0.05 vs no agonist; § significant reversal of the inhibitory effects. Values represent mean ± SEM from 3 separate experiments, each conducted in triplicates.

for p27<sup>Kip1</sup> in A<sub>2B</sub> receptor-mediated regulation of HCASMC proliferation.

Next, we tested whether adenylyl cyclase and PKA mediate the effects of 2-chloroadenosine on p27<sup>Kip1</sup> and HCASMC growth via A<sub>2B</sub> receptors. 2-Chloroadenosine inhibited Skp2 and upregulated p27<sup>Kip1</sup> in the absence (Figure 8A) but not in the presence of the adenylyl cyclase inhibitor myristoylated trifluoroacetate or the PKA inhibitor 2',5'-dideoxyadenosine (Figure 8A). Also, the inhibitory effects of 2-chloroadenosine on HCASMC DNA synthesis were blocked by PKA and adenylyl cyclase inhibitors (Figure 8A). To further confirm the link between cAMP and p27<sup>Kip1</sup> in mediating the inhibitory effects of 2-chloroadenosine via A<sub>2B</sub> receptors, we assessed the effects of 2-chloroadenosine on DNA synthesis in HCASMCs, where p27<sup>Kip1</sup> expression was silenced. Treatment




**Figure 6.** Inhibitory effects of 0.5 μmol/L of 2-chloroadenosine (CI-Ad) on levels of hyper-phosphorylated (Hyper-P) and hypo-phosphorylated (Hypo-P) pRb, phosphorylated ERK1/2 (ERK1/2-P), total ERK1/2, phosphorylated Akt (Akt-P), total Akt, cyclin A, cyclin D1, S-phase kinase-associated protein-2 (Skp2), and p27<sup>Kip1</sup> (p27) expression in human coronary artery smooth muscle cells (HCASMCs) in the absence (–siRNA) and presence (+siRNA) of A<sub>2B</sub> receptor siRNA. Sub-confluent monolayers of HCASMCs were growth-arrested for 36 hours in 0.4% BSA and were treated and stimulated with 2.5% fetal calf serum (FCS) for 48 hours. Cell lysates were subsequently analyzed by Western blotting. The modulatory effects of CI-Ad on the signaling and cell cycle-regulating proteins were lost in the absence of A<sub>2B</sub> receptors. Bar graphs depict the optical density (OD) or OD ratio (phosphorylated ERK1/2 to ERK1/2; phosphorylated Akt to Akt; cyclin D1 to β-actin; cyclin A to β-actin; p27<sup>Kip1</sup> to β-actin; Skp2 to β-actin) for the Western blots. \*P < 0.05 versus control. Values represent mean ± SEM from 3 separate experiments, each conducted in triplicates.

of HCASMCs with p27<sup>Kip1</sup> siRNA silenced p27<sup>Kip1</sup> expression compared with cells treated with negative-control siRNA (Figure 8B). 2-Chloroadenosine inhibited DNA synthesis in HCASMCs treated with negative-control siRNA, but not in HCASMCs where p27<sup>Kip1</sup> was silenced. Similar to 2-chloroadenosine, MECA and 8-bromo-cAMP inhibited DNA synthesis in HCASMCs treated with negative-control siRNA, but not in cells in which p27<sup>Kip1</sup> was silenced (Figure 8C).

In serum-starved HCASMCs, silencing of A<sub>2B</sub> receptors with siRNA resulted in a significant increase in DNA synthesis, and these effects were further enhanced by the A<sub>1</sub> adenosine receptor agonist CPA (Figure 9). Pretreatment with DPCPX, an A<sub>1</sub> receptor antagonist, blocked the stimulatory effect of A<sub>2B</sub> silencing under basal conditions and in response to CPA. These findings indicate that in the absence of A<sub>2B</sub> receptors, endogenous adenosine induces HCASMC growth via A<sub>1</sub> receptors.

Morphometric analysis of carotid arteries showed significant intimal thickening after balloon injury, and this was significantly inhibited in rats receiving 2-chloroadenosine for 7 days. As shown in Figure 10A, compared with the placebo group (n=7; intima 37424 ± 18371 pixels), the neo-intima formation was reduced by 71% in rats receiving periarterial 2-chloroadenosine (n=7; 10352 ± 2824; P < 0.05 versus





**Figure 7.** **A**, Concentration-dependent modulatory effects of 2-chloroadenosine (CI-Ad) on S-phase kinase-associated protein-2 (Skp2) and p27<sup>Kip1</sup> (p27) levels in human coronary artery smooth muscle cells (HCASMCs). Treatment of HCASMCs with CI-Ad for 48 hours downregulated the expression of Skp2 and upregulated the expression of p27<sup>Kip1</sup> (p27). **B**, Effects of CI-Ad on p27<sup>Kip1</sup> expression and DNA synthesis in HCASMCs with downregulated A<sub>2B</sub> receptors. Compared with HCASMCs treated with negative-control siRNA (-Si RNA or siControl), CI-Ad -induced expression of p27<sup>Kip1</sup> and inhibition of DNA synthesis was abrogated in HCASMCs treated with siRNA against A<sub>2B</sub> receptors (+SiRNA or A2B-siRNA). The optical density (OD) ratio in the bar graphs represents ratio of Skp2, p27<sup>Kip1</sup>, or A<sub>2B</sub> receptor to β-actin. Values represent mean±SEM from 3 separate experiments, each conducted in triplicates.

placebo). The media and lumen areas did not significantly differ between the placebo and the 2-chloroadenosine-treated group (Table S2); however, the intimal/medial ratio was significantly reduced in animals receiving 2-chloroadenosine (Table S2). In carotid arteries obtained from animals receiving placebo, Ki67-positive cells (indicating proliferating of VSMCs) were observed (Figure 10B). As compared with the placebo group, a significant decrease in Ki67-positive VSMCs was observed in arteries obtained from animals treated with 2-chloroadenosine (Figure 10B). Treatment with 2-chloroadenosine was not associated with any toxic adverse effects. In this regard, the WBC count, RBC count, and hematocrit did not differ between placebo and 2-chloroadenosine-treated groups (Table S2). To assess whether Skp2 and p27<sup>Kip1</sup> are involved in mediating the inhibitory effects of 2-chloroadenosine on intimal formation after balloon injury, we analyzed their levels in carotid lysates. As shown in Figure 10C, compared with placebo (n=5), treatment with 2-chloroadenosine (n=5) downregulated the expression of Skp2 and upregulated the expression of p27<sup>Kip1</sup>.

In the studies described earlier, we used 2-chloroadenosine rather than adenosine because adenosine is rapidly


metabolized (necessitating frequent treatments), whereas 2-chloroadenosine is resistant to metabolism (allowing once daily treatments). To make sure that adenosine per se qualitatively has the same effects as 2-chloroadenosine, we assessed the effects of adenosine on HCASMC proliferation. As shown in Figure 11A, adenosine inhibited DNA synthesis in a concentration-dependent manner. As expected, when cells were treated daily, adenosine was ≈10-fold less potent than 2-chloroadenosine in inhibiting HCASMC proliferation. Moreover, similar to 2-chloroadenosine, the inhibitory effects of adenosine were blocked by the A<sub>2B</sub> receptor antagonist MRS1754 (Figure 11B). To assess whether decreased potency of adenosine is caused by its catabolism by adenosine deaminase and adenosine kinase, we assessed the growth inhibitory effects of adenosine in the presence and absence of adenosine deaminase and adenosine kinase inhibitors EHNA and IDO. The inhibitory effects of adenosine on cell number were significantly enhanced by EHNA+IDO (Figure 11B), and this effect was reversed by the A<sub>2B</sub> receptor antagonist MRS1754, suggesting that adenosine catabolism is responsible for its reduced inhibitory potency in HCASMCs. To assess whether adenosine, like 2-chloroadenosine, inhibits HCASMC growth via upregulation of p27<sup>Kip1</sup> and downregulation of Skp2, we assessed adenosine's effect on the expression of both p27<sup>Kip1</sup> and Skp2. As shown in Figure 11C, treatment of HCASMCs with adenosine upregulated p27<sup>Kip1</sup> and downregulated Skp2 expression. Taken together, these observations suggest that adenosine, although less potent than 2-chloroadenosine, inhibits HCASMC growth via similar mechanisms.

## Discussion

Our experiments demonstrate that exogenous, as well as endogenous, adenosine inhibits mitogen-induced proliferation and migration of HCASMCs. In support of this conclusion, we observe that treatment of HCASMCs with a metabolically stable adenosine analog (2-chloroadenosine) or with agents that increase endogenous adenosine (EHNA plus IDO) inhibits HCASMC DNA synthesis, cell proliferation, and cell migration.

Our results also support the conclusion that adenosine inhibits proliferation of HCASMCs via activation of A<sub>2B</sub> receptors. CPA, CGS21680, and IB-MECA are selective A<sub>1</sub> receptor, A<sub>2A</sub> receptor, and A<sub>3</sub> receptor agonists, respectively; and DPCPX, SCH442416, and VUF5574 are selective A<sub>1</sub> receptor, A<sub>2A</sub> receptor, and A<sub>3</sub> receptor antagonists, respectively. Because neither low concentrations of CPA, CGS21680, nor IB-MECA inhibit HCASMC proliferation and because neither DPCPX, SCH442416, nor VUF5574 blocks the inhibitory effects of 2-chloroadenosine on HCASMC proliferation, it is highly unlikely that A<sub>1</sub>, A<sub>2A</sub>, or A<sub>3</sub> receptors mediate the anti-mitogenic effects of adenosine on HCASMCs. Because there are only 4 known adenosine receptor subtypes and 3 of the 4 are ruled out, by the process of elimination, the A<sub>2B</sub> receptor most likely is the receptor mediating the effects of adenosine on HCASMC growth. MECA and NECA are adenosine receptor agonists that activate multiple adenosine receptor subtypes, including A<sub>2B</sub> receptors, and MRS1754 is an adenosine receptor antagonist that blocks selectively A<sub>2B</sub> receptors. The fact that MECA and NECA mimic the effects






**Figure 8.** A, Protein kinase A (PKA) and adenyl cyclase (AC) pathways mediate the inhibitory effects of 2-chloroadenosine (CI-Ad) on human coronary artery smooth muscle cell (HCASMC) proliferation via modulation of S-phase kinase-associated protein-2 (Skp2) and p27<sup>Kip1</sup>. Western blots show Skp2 and p27<sup>Kip1</sup> expression in HCASMCs treated with CI-Ad (0.5  $\mu$ M) in presence or absence of a protein kinase A inhibitor (myristoylated trifluoroacetate, frag 14–22; 10  $\mu$ M/L; PKA-I) or adenyl cyclase inhibitor (2',5' dideoxyadenosine; 1  $\mu$ M/L; AC-I) for 48 hours. Treatment of HCASMCs with CI-Ad upregulated p27<sup>Kip1</sup> and downregulated Skp2, and these effects were abrogated by both PKA-I and AC-I. Both PKA-I and AC-I also reversed the inhibitory effects of CI-Ad on DNA synthesis in HCASMCs. \* $P$ <0.05, no CI-Ad (–CI-Ad) vs CI-Ad (+CI-Ad); §significant reversal of the inhibitory effects. B, Role of p27<sup>Kip1</sup> in mediating the growth inhibitory actions of CI-Ad in HCASMCs. In contrast to HCASMCs treated with control siRNA (–Si RNA or Si-Con), treatment of HCASMCs with p27<sup>Kip1</sup> siRNA (+Si RNA or p27-siRNA) blocked CI-Ad –induced expression of p27<sup>Kip1</sup> (Western blots). The inhibitory effects of CI-Ad on DNA synthesis were abrogated in HCASMCs with silenced p27<sup>Kip1</sup>. C, Similar to CI-Ad, the inhibitory effects of 5'-N-methylcarboxamidoadenosine (MECA) and 8-bromo-cAMP (Br-cAMP) were abrogated in HCASMCs treated with p27<sup>Kip1</sup> siRNA (p27-siRNA) but not in HCASMCs treated with control siRNA (si-Control). \* $P$ <0.05 vs control; §significant reversal of the inhibitory effects. Values represent mean $\pm$ SEM from 3 separate experiments, each conducted in triplicates. The optical density (OD) ratio in the bar graphs represents Skp2 or p27<sup>Kip1</sup> to  $\beta$ -actin ratio.

of 2-chloroadenosine on HCASMC proliferation and the fact that MRS1754 attenuates the inhibitory effects of 2-chloroadenosine and MECA on HCASMC proliferation corroborate the conclusion that A<sub>2B</sub> receptors mediate the inhibitory effects of adenosine on HCASMC proliferation. This conclusion is confirmed by our findings that the inhibitory effects of MECA, NECA, and 2-chloroadenosine on HCASMC proliferation are blocked by siRNA against A<sub>2B</sub> receptors.

Multiple pro-mitogenic pathways—including ERK1/2 and Akt—are involved in triggering the proliferative response of mitogens generated at sites of vascular dysfunction or injury. These early signaling pathways trigger proliferation of HCASMCs by upregulating cell cycle regulatory proteins—such as cyclin D and cyclin A—that promote cell-cycle progress or by downregulating regulatory proteins—such as p27<sup>Kip1</sup>—that retard cell-cycle progression.<sup>45,47</sup> The present study shows that treatment with 2-chloroadenosine or MECA, but not CPA, CGS21680, or IB-MECA, inhibits phosphorylation of ERK1/2 and Akt, decreases expression of Skp2, increases levels of p27<sup>Kip1</sup>, decreases expression of cyclin

D1, inhibits hyper-phosphorylation of Rb, and downregulates expression of cyclin A. These results are entirely consistent with the proposed mechanism of adenosine's antiproliferative action outlined in Figure 1. The role of A<sub>2B</sub> receptors in modulating these key signaling mechanisms to negatively influence cell proliferation is further supported by our observation that the effects of 2-chloroadenosine and MECA on these signaling pathways are blocked by the A<sub>2B</sub> receptor antagonist MRS1754 and by silencing of A<sub>2B</sub> receptors using siRNA. Therefore, these findings corroborate the concept that A<sub>2B</sub> receptor activation causes a realignment of signaling pathways to inhibit HCASMC proliferation by the mechanism shown in Figure 1.


Skp2 is an F-box protein of SCF<sup>Skp2</sup> ubiquitin ligase and therefore promotes polyubiquitination of and subsequent proteolysis of p27<sup>Kip1</sup>.<sup>30,49</sup> Because p27<sup>Kip1</sup> binds to and inhibits the function of cyclin–Cdk complexes (such as cyclin D/Cdk4/6), an increase in p27<sup>Kip1</sup> levels would inhibit the function of cyclin D. Thus, we hypothesize that via A<sub>2B</sub> receptors, adenosine inhibits HCASMC proliferation in part by downregulating Skp2 and upregulating p27<sup>Kip1</sup>. Consistent with this



**Figure 9.** Bar graphs depict the balanced regulation of human coronary artery smooth muscle cell (HCASMC) proliferation by A<sub>2B</sub> and A<sub>1</sub> adenosine receptors. In serum-starved HCASMCs, silencing of A<sub>2B</sub> receptors with siRNA (+A<sub>2B</sub>-siRNA) resulted in a significant increase in DNA synthesis, and these effects were further enhanced by the A<sub>1</sub> adenosine receptor agonist N<sup>6</sup>-cyclopentyladenosine (CPA; 100 nmol/L). Pretreatment with 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; 10 nmol/L), an A<sub>1</sub> receptor antagonist, blocked the stimulatory effect of A<sub>2B</sub> silencing under basal conditions and in response to CPA. These findings indicate that downregulation of A<sub>2B</sub> receptors increases DNA synthesis under basal conditions, suggesting that in the absence of A<sub>2B</sub> receptors, endogenous adenosine induces HCASMC growth via A<sub>1</sub> receptors. This is further supported by the observation that CPA further stimulated DNA synthesis, and this effect was blocked by DPCPX. \**P*<0.05, vs no siRNA (-siRNA) and vs control siRNA (+si-Control) in medium with 0.4% BSA; §significant reversal of the proliferative effects of A<sub>2B</sub> siRNA with or without CPA. Values represent mean±SEM from 3 separate experiments using separate cultures, each conducted in triplicates.


notion, our results show that treatment with 2-chloroadenosine reduces Skp2 expression, and this is accompanied by a simultaneous increase in p27<sup>Kip1</sup> levels. Using pharmacological agonists and antagonists and molecular silencing of A<sub>2B</sub> receptors, we demonstrate that the modulatory effects of adenosine on Skp2 and p27<sup>Kip1</sup> are A<sub>2B</sub> receptor-mediated. Consistent with our contention that the anti-mitogenic effects of adenosine are mediated in part by inhibiting the proteolytic actions of Skp2 on p27<sup>Kip1</sup>, we also observe that via A<sub>2B</sub> receptors (pharmacological and molecular approaches), 2-chloroadenosine as well as MECA inhibit cyclin D-dependent downstream signaling, that is, hyper-phosphorylation of Rb and expression of cyclin A (Figure 1). These modulatory actions of 2-chloroadenosine on ERK1/2, Akt, Skp2, p27<sup>Kip1</sup>, cyclin D, Rb, and cyclin A are also consistent with our observation that 2-chloroadenosine increases the percentage of cells in the G0/G1 phase of the cell cycle, although decreasing the percentage of cells in the S and G2/M phases of the cell cycle.

Our studies are consistent with the concept that the proximal signaling mechanism by which A<sub>2B</sub> receptors inhibit proliferation involves the adenylyl cyclase/cAMP/PKA axis (Figure 1). A<sub>2B</sub> receptors induce cAMP formation via activation of adenylyl cyclase.<sup>50</sup> Therefore, cAMP may be involved in mediating the effects of 2-chloroadenosine on ERK1/2, Akt, and Skp2. Our finding that the inhibitory effects of 2-chloroadenosine on HCASMC proliferation are significantly abrogated by inhibition of adenylyl cyclase and PKA are consistent with the hypothesis that A<sub>2B</sub>-mediated cAMP production participates in the anti-mitogenic effects of 2-chloroadenosine. We also observe that in HCASMCs with siRNA-silenced



**Figure 10.** **A**, Inhibitory effects of 2-chloroadenosine (CI-Ad) on intimal thickening after balloon injury. Image shows representative photomicrographs (40× magnification) of the cross sections of rat carotid arteries 7 days after balloon injury. Compared with rats receiving vehicle (placebo), intimal thickening was significantly reduced in rats exposed peri-arterially with CI-Ad (20 μmol/L in 25% pluronic gel). Bar graph compares the intimal area in rats receiving vehicle (n=7) versus CI-Ad (n=7) after injury. Data are mean±SEM. **B**, Inhibitory effects of CI-Ad on proliferation of vascular smooth muscle cells (VSMCs) in the intima 7 days after balloon injury. Image shows representative photomicrographs (40× magnification) of cross sections of carotid arteries stained for Ki67-positive proliferating VSMCs. Bar graph compares the number of Ki67-positive cells in placebo versus CI-Ad-treated groups. Data are mean±SEM. **C**, Effects of CI-Ad on neointimal expression of S-phase kinase-associated protein-2 (Skp2) and p27<sup>Kip1</sup> proteins in vivo. Rats were treated with placebo (n=5) or CI-Ad (20 μmol/L in 25% pluronic gel, n=5) and were euthanized on day 8. Carotid arteries were snap-frozen in liquid nitrogen. Subsequently, segments from placebo or CI-Ad-treated animals were homogenized, lysed, and proteins analyzed using Western blotting. Bar graph depicts the changes in optical density (OD) of Skp2 or p27<sup>Kip1</sup> normalized to β-actin. \**P*<0.05 vs placebo.

A<sub>2B</sub> receptors, 2-chloroadenosine-induced cAMP production is abrogated and the anti-mitogenic effects of 2-chloroadenosine and MECA, but not 8-bromo-cAMP, are prevented. Together, these data suggest that the antiproliferative effects of 2-chloroadenosine are mediated by cAMP produced via A<sub>2B</sub> receptor activation. The involvement of cAMP in mediating the effects of 2-chloroadenosine on Skp2 and p27<sup>Kip1</sup> via A<sub>2B</sub> receptors is supported by the fact that the inhibitory effects of 2-chloroadenosine on Skp2 expression and the concomitant stimulatory effects of 2-chloroadenosine on p27<sup>Kip1</sup> levels are attenuated by inhibition of adenylyl cyclase, PKA, and A<sub>2B</sub> receptors and abrogated in HCASMCs lacking A<sub>2B</sub> receptors. Taken together and as shown in Figure 1, our findings suggest that the anti-mitogenic effects of adenosine are mediated via



**Figure 11.** A, Concentration (0, 0.01, 0.1, 1 μmol/L)–response relationships for the inhibition of DNA synthesis (<sup>3</sup>H-thymidine incorporation) by 2-chloroadenosine (Cl-Ad) and adenosine (Ad) in human coronary artery smooth muscle cells (HCASMCs). B, The effects of 100 nmol/L of 2-chloroadenosine (Cl-Ad) and adenosine (Ad) on cell number in the presence and absence of MRS1754 (MRS; selective A<sub>2B</sub> antagonist, 100 nmol/L) or inhibitory effects of adenosine in presence or absence of erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; 1 μmol/L) plus 5-iodotubercidin (IDO; 0.1 μmol/L) and with or without MRS1754 (100 nmol/L). C, The effects of adenosine on p27<sup>Kip1</sup> and S-phase kinase-associated protein-2 (Skp2) expression in HCASMCs treated with or without adenosine (Ad; 100 nmol/L) for 48 hours. \**P*<0.05 vs no treatment; §*P*<0.05 significant reversal of inhibitory effects; #*P*<0.05 significant increase of inhibitory effects. Values represent mean±SEM from 3 separate experiments using separate HCASMCs, each conducted in triplicate. The optical density (OD) ratio in the bar graphs represents Skp2 or p27<sup>Kip1</sup> to β-actin ratio.

A<sub>2B</sub> receptor stimulation of cAMP production and sequential activation of PKA. This concept is supported by a previous report that cAMP inhibits neointima formation via PKA activation and by downregulating Skp2 and upregulating p27<sup>Kip1</sup> in rat aortic VSMCs.<sup>38,39,51</sup>

Recent studies provide strong evidence for a major role of p27<sup>Kip1</sup> upregulation in mediating anti-mitogenic actions in many cell types.<sup>38,51–53</sup> Decreased or defective expression of p27<sup>Kip1</sup> is linked to proliferative disorders, including atherosclerosis, restenosis after balloon injury, and cancer. In animal models, molecular approaches for targeted upregulation

of p27<sup>Kip1</sup> prevent injury-induced intimal thickening, as well as cancer cell growth.<sup>53</sup> Our finding that 2-chloroadenosine induces p27<sup>Kip1</sup> expression via A<sub>2B</sub> receptors suggests that p27<sup>Kip1</sup> mediates in part the anti-mitogenic effects of A<sub>2B</sub> receptors. Consistent with this notion, our experiments show that the stimulatory effects of 2-chloroadenosine on p27<sup>Kip1</sup> expression and inhibitory effects on HCASMC proliferation are blocked by A<sub>2B</sub> receptor antagonism or knockdown of A<sub>2B</sub> receptors. Moreover, silencing of p27<sup>Kip1</sup> in HCASMCs abrogates the inhibitory effects of 2-chloroadenosine on cell proliferation and the stimulatory effects of 2-chloroadenosine on p27<sup>Kip1</sup> expression. Similar to 2-chloroadenosine, the inhibitory effects of MECA and cAMP are abrogated in HCASMCs with silenced p27<sup>Kip1</sup>, suggesting that p27<sup>Kip1</sup> is a key mediator for the anti-mitogenic actions of 2-chloroadenosine, which requires the sequential involvement of A<sub>2B</sub> receptors and cAMP generation.

To confirm that the observed anti-mitogenic effects of adenosine in HCASMCs in vitro would also translate to preventing vascular remodeling in vivo, we investigated the effects of 2-chloroadenosine on injury-induced neointima formation. In this regard, we used the rat carotid artery injury model. The present study showed that treatment of rats peri-arterially with 2-chloroadenosine significantly inhibited intimal thickening. Moreover, the inhibitory effects of 2-chloroadenosine on neointima formation were associated with downregulation of Skp2 and upregulation of p27<sup>Kip1</sup>. Taken together, these findings suggest that 2-chloroadenosine prevents intimal thickening in part by downregulating the expression of Skp2 and upregulating p27<sup>Kip1</sup> levels. These findings are consistent with recent reports that injury-induced intimal thickening<sup>54,55</sup> and high-lipid diet-induced atherosclerosis<sup>56</sup> are increased in mice lacking A<sub>2B</sub> receptors, suggesting that the anti-vasoocclusive effects of adenosine are A<sub>2B</sub> receptor-mediated. Interestingly, in the present study, 2-chloroadenosine reduced neointimal area without altering lumen area. This suggests that 2-chloroadenosine blocked both neointimal formation and remodeling such that lumen area remained constant with a more normal intimal lining.

In mast cells<sup>57</sup> and cardiac fibroblasts,<sup>58</sup> A<sub>2B</sub> receptors couple to protein kinase C, and it is conceivable that this also occurs in HCASMCs. However, if so, this would probably not contribute to inhibition of HCASMC proliferation because our previous studies suggest that PKC is involved in stimulating, rather than inhibiting, VSMC proliferation.<sup>59</sup>

Our finding that application of 2-chloroadenosine peri-arterially inhibits injury-induced intimal thickening has potential therapeutic significance. Restenosis after balloon angioplasty is a major post-angioplasty-associated clinical problem. Because abnormal growth of HCASMCs occurs mainly during the first 7 days after angioplasty<sup>47</sup> and peri-arterial application of 2-chloroadenosine inhibits intimal thickening, its peri-arterial application may prevent restenosis after balloon angioplasty in humans. Peri-arterial application may also resolve the limitations associated with the rapid clearance and short half-life of adenosine or its analogs.

Our data provide evidence that 2-chloroadenosine is effective in inhibiting HCASMC growth and injury-induced neointima formation. Likely, adenosine would mimic the



antiproliferative/anti-vasoocclusive effects of 2-chloro-adenosine. Indeed, our findings that adenosine inhibits HCASMC growth, inhibits Skp2 expression, and induces p27<sup>Kip1</sup> expression suggest that adenosine would also mediate vascular protective actions. However, because of rapid catabolism of adenosine by adenosine kinase and adenosine deaminase, adenosine likely would be less potent than 2-chloroadenosine. Although adenosine's effect on neointima formation in vivo was not assessed in the present study, experiments using A<sub>2B</sub> receptor knockout mice provide evidence for enhanced proliferation of VSMCs following endothelial denudation.<sup>53,54</sup> This suggests that endogenous adenosine indeed is capable of suppressing intimal growth and vascular remodeling, which lead to vascular occlusion. Future studies using adenosine in pluronic acid gels are required to confirm whether adenosine has a physiological role in regulating growth of VSMCs.

Experiments by Shen et al<sup>60,61</sup> demonstrate that A<sub>1</sub> receptors, rather than A<sub>2B</sub> receptors, are dominant in porcine coronary artery smooth muscle cells and that, in this setting, adenosine stimulates proliferation via A<sub>1</sub> receptor activation. Because A<sub>1</sub> receptors inhibit, rather than stimulate, adenylyl cyclase, the findings of Shen et al are highly consistent with the mechanism proposed in Figure 1. Indeed we find that silencing of A<sub>2B</sub> receptors augments HCASMC proliferation via activation of A<sub>1</sub> receptors by endogenous adenosine. Taken together, our finding and the findings of Shen et al suggest the possibility that the ratio of A<sub>1</sub> to A<sub>2B</sub> receptors in HCASMCs in individual patients contributes significantly to the risk of coronary artery disease. If true, this would be an extremely important concept because this novel idea would suggest that administration of A<sub>1</sub> receptor antagonists would be protective in patients with a high A<sub>1</sub> to A<sub>2B</sub> ratio, whereas an A<sub>2B</sub> receptor agonist would be preferred in patients with a high A<sub>2B</sub> to A<sub>1</sub> ratio (ie, personalized medicine). However, a caveat is that A<sub>2B</sub> receptors when activated chronically can induce profibrotic and proinflammatory effects.<sup>62,63</sup> Therefore, it may be important to limit the duration of treatment with A<sub>2B</sub> receptor agonists to just the critical time period in which HCASMC proliferation occurs in response to injury.

It is interesting that in the absence of A<sub>2B</sub> receptors, A<sub>1</sub> receptor activation leads to HCASMC proliferation. Given that A<sub>1</sub> receptors have much higher affinity for adenosine, why would their effect not predominate? There are reports that A<sub>1</sub> receptors form heterodimers with A<sub>2A</sub> receptors and  $\beta$ -adrenoceptors and that heterodimer formation blocks A<sub>1</sub> receptor signaling.<sup>62,63</sup> Therefore, one possibility is that in HCASMCs, A<sub>2B</sub> receptors directly block A<sub>1</sub> receptor signaling via heterodimerization. Another possibility is that A<sub>2B</sub>/Gs-mediated stimulation of adenylyl cyclase overrides A<sub>1</sub>/Gi-mediated signaling, despite higher agonist binding to A<sub>1</sub> receptors.

In conclusion, we provide strong evidence that (1) adenosine inhibits HCASMC proliferation and migration; (2) the inhibitory effects of adenosine on HCASMC proliferation are mediated via A<sub>2B</sub> receptor activation of adenylyl cyclase, leading to the accumulation of cAMP and stimulation of PKA; (3) PKA inhibits HCASMC proliferation by blocking multiple signaling pathways (ERK1/2, Akt, and Skp2) that converge

at cyclin D—the net result being a reduced expression and function of this key G1 cyclin that governs cell-cycle progression; (4) this mechanism is operative in vivo; and (5) if the A<sub>2B</sub> receptor system is deficient, A<sub>1</sub> receptors become dominant and increase HCASMC proliferation.

## Perspectives

Activation of A<sub>2B</sub> receptors by adenosine inhibits HCASMC proliferation. This effect is profoundly efficacious because the A<sub>2B</sub> receptor/adenylyl cyclase/cAMP/PKA pathway blocks cell cycle progression by inhibiting multiple downstream signaling events that are required for cyclin D production and function. Because A<sub>2B</sub> and A<sub>1</sub> receptors have opposing effects on HCASMC proliferation, pharmacological activation of A<sub>2B</sub> receptors or inhibition of A<sub>1</sub> receptors or both may prevent vascular remodeling associated with coronary artery disease, hypertension, atherosclerosis, and restenosis.

## Acknowledgments

We thank Doris Müller (University Hospital Zurich, Department of Reproductive Endocrinology, Zurich, Switzerland) for cell growth and protein analysis.

## Sources of Funding

This work was financially supported by the Olten Heart Foundation (to R.K. Dubey); the Swiss National Science Foundation Grant No. IZERO-142213/1 and Grant No. 31003A-138067 to R.K. Dubey; and the National Institutes of Health grants NS087978, HL109002, DK091190, HL069846, DK068575, and DK079307 to E.K. Jackson).

## Disclosures

None.

## References

1. Dubey RK, Jackson EK, Rupprecht HD, Sterzel RB. Factors controlling growth and matrix production in vascular smooth muscle and glomerular mesangial cells. *Curr Opin Nephrol Hypertens*. 1997;6:88–105.
2. Jackson EK, Gillespie DG. Regulation of cell proliferation by the guanosine-adenosine mechanism: role of adenosine receptors. *Physiol Rep*. 2013;1:e00024. doi: 10.1002/phy2.24.
3. Jackson EK, Ren J, Gillespie DG, Dubey RK. Extracellular 2,3-cyclic adenosine monophosphate is a potent inhibitor of preglomerular vascular smooth muscle cell and mesangial cell growth [corrected]. *Hypertension*. 2010;56:151–158. doi: 10.1161/HYPERTENSIONAHA.110.152454.
4. Dubey RK, Gillespie DG, Mi Z, Rosselli M, Keller PJ, Jackson EK. Estradiol inhibits smooth muscle cell growth in part by activating the cAMP-adenosine pathway. *Hypertension*. 2000;35(1 pt 2):262–266. doi: 10.1161/01.HYP.35.1.262.
5. Dubey RK, Gillespie DG, Jackson EK. Adenosine inhibits collagen and total protein synthesis in vascular smooth muscle cells. *Hypertension*. 1999;33(1 pt 2):190–194. doi: 10.1161/01.HYP.33.1.190.
6. Dubey RK, Gillespie DG, Mi Z, Suzuki F, Jackson EK. Smooth muscle cell-derived adenosine inhibits cell growth. *Hypertension*. 1996;27(3 pt 2):766–773.
7. Dubey RK, Gillespie DG, Osaka K, Suzuki F, Jackson EK. Adenosine inhibits growth of rat aortic smooth muscle cells. Possible role of A<sub>2B</sub> receptor. *Hypertension*. 1996;27(3 pt 2):786–793. doi: 10.1161/01.HYP.27.3.786.
8. Dubey RK, Mi Z, Gillespie DG, Jackson EK. Cyclic AMP-adenosine pathway inhibits vascular smooth muscle cell growth. *Hypertension*. 1996;28:765–771. doi: 10.1161/01.HYP.28.5.765.
9. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Adenosine inhibits growth of human aortic smooth muscle cells via A<sub>2B</sub> receptors. *Hypertension*. 1998;31(1 Pt 2):516–521. doi: 10.1161/01.HYP.31.1.516.
10. Dubey RK, Rosselli M, Gillespie DG, Mi Z, Jackson EK. Extracellular 3',5'-cAMP-adenosine pathway inhibits glomerular mesangial cell

- growth. *J Pharmacol Exp Ther*. 2010;333:808–815. doi: 10.1124/jpet.110.166371.
11. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Adenosine inhibits PDGF-induced growth of human glomerular mesangial cells via A<sub>2B</sub> receptors. *Hypertension*. 2005;46:628–634. doi: 10.1161/01.HYP.0000178464.63393.88.
  12. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts: role of A<sub>2B</sub> receptors. *Circulation*. 1997;96:2656–2666.
  13. Dubey RK, Gillespie DG, Jackson EK. Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts: role of A<sub>2B</sub> receptors. *Hypertension*. 1998;31:943–948. doi: 10.1161/01.HYP.31.4.943.
  14. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Cardiac fibroblasts express the cAMP-adenosine pathway. *Hypertension*. 2000;36:337–342. doi: 10.1161/01.HYP.36.3.337.
  15. Dubey RK, Gillespie DG, Zacharia LC, Mi Z, Jackson EK. A<sub>2B</sub> receptors mediate the antimitogenic effects of adenosine in cardiac fibroblasts. *Hypertension*. 2001;37(2 pt 2):716–721. doi: 10.1161/01.HYP.37.2.716.
  16. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Endogenous cyclic AMP-adenosine pathway regulates cardiac fibroblast growth. *Hypertension*. 2001;37:1095–1100. doi: 10.1161/01.HYP.37.4.1095.
  17. Dubey RK, Gillespie DG, Jackson EK. A<sub>2B</sub> adenosine receptors stimulate growth of porcine and rat arterial endothelial cells. *Hypertension*. 2002;39(2 pt 2):530–535. doi: 10.1161/hy0202.103075.
  18. Jackson EK, Gillespie DG. Extracellular 2',3'-cAMP and 3',5'-cAMP stimulate proliferation of preglomerular vascular endothelial cells and renal epithelial cells. *Am J Physiol Renal Physiol*. 2012;303:F954–F962. doi: 10.1152/ajprenal.00335.2012.
  19. Ryzhov S, McCaleb JL, Goldstein AE, Biaggioni I, Feoktistov I. Role of adenosine receptors in the regulation of angiogenic factors and neovascularization in hypoxia. *J Pharmacol Exp Ther*. 2007;320:565–572. doi: 10.1124/jpet.106.114850.
  20. Ryzhov S, Solenkova NV, Goldstein AE, Lamparter M, Fleenor T, Young PP, Greelish JP, Byrne JG, Vaughan DE, Biaggioni I, Hatzopoulos AK, Feoktistov I. Adenosine receptor-mediated adhesion of endothelial progenitors to cardiac microvascular endothelial cells. *Circ Res*. 2008;102:356–363. doi: 10.1161/CIRCRESAHA.107.158147.
  21. Ryzhov S, Biktasova A, Goldstein AE, Zhang Q, Biaggioni I, Dikov MM, Feoktistov I. Role of JunB in adenosine A<sub>2B</sub> receptor-mediated vascular endothelial growth factor production. *Mol Pharmacol*. 2014;85:62–73. doi: 10.1124/mol.113.088567.
  22. Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, Schönfeld C, Löffler M, Reyes G, Duzenko M, Karhausen J, Robinson A, Westerman KA, Coe IR, Colgan SP. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. *J Exp Med*. 2005;202:1493–1505. doi: 10.1084/jem.20050177.
  23. Eltzschig HK. Adenosine: an old drug newly discovered. *Anesthesiology*. 2009;111:904–915. doi: 10.1097/ALN.0b013e3181b060f2.
  24. Eltzschig HK, Köhler D, Eckle T, Kong T, Robson SC, Colgan SP. Central role of Spl-regulated CD39 in hypoxia/ischemia protection. *Blood*. 2009;113:224–232. doi: 10.1182/blood-2008-06-165746.
  25. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. *N Engl J Med*. 2011;364:656–665. doi: 10.1056/NEJMr0910283.
  26. Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. *N Engl J Med*. 2012;367:2322–2333. doi: 10.1056/NEJMr1205750.
  27. Eltzschig HK. Extracellular adenosine signaling in molecular medicine. *J Mol Med (Berl)*. 2013;91:141–146. doi: 10.1007/s00109-013-0999-z.
  28. Hong J, Qian T, Le Q, Sun X, Wu J, Chen J, Yu X, Xu J. NGF promotes cell cycle progression by regulating D-type cyclins via PI3K/Akt and MAPK/Erk activation in human corneal epithelial cells. *Mol Vis*. 2012;18:758–764.
  29. Song GJ, Leslie KL, Barrick S, Mamonova T, Fitzpatrick JM, Drombosky KW, Peyser N, Wang B, Pellegrini M, Bauer PM, Friedman PA, Mierke DF, Bisello A. Phosphorylation of ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) by Akt promotes stability and mitogenic function of S-phase kinase-associated protein-2 (Skp2). *J Biol Chem*. 2015;290:2879–2887. doi: 10.1074/jbc.M114.609768.
  30. Hara T, Kamura T, Nakayama K, Oshikawa K, Hatakeyama S, Nakayama K. Degradation of p27<sup>Kip1</sup> at the G<sub>0</sub>-G<sub>1</sub> transition mediated by a Skp2-independent ubiquitination pathway. *J Biol Chem*. 2001;276:48937–48943. doi: 10.1074/jbc.M107274200.
  31. Roy A, Banerjee S. p27 and leukemia: cell cycle and beyond. *J Cell Physiol*. 2015;230:504–509. doi: 10.1002/jcp.24819.
  32. Casimiro MC, Velasco-Velázquez M, Aguirre-Alvarado C, Pestell RG. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present. *Expert Opin Investig Drugs*. 2014;23:295–304. doi: 10.1517/13543784.2014.867017.
  33. Choi YJ, Anders L. Signaling through cyclin D-dependent kinases. *Oncogene*. 2014;33:1890–1903. doi: 10.1038/ncr.2013.137.
  34. Morgan DO. *The Cell Cycle: Principles of Control*. London, UK: New Science Press; 2007.
  35. Dubey RK, Gillespie DG, Shue H, Jackson EK. A<sub>2B</sub> receptors mediate antimitogenesis in vascular smooth muscle cells. *Hypertension*. 2000;35(1 Pt 2):267–272.
  36. Jackson EK, Gillespie DG, Dubey RK. 2'-AMP and 3'-AMP inhibit proliferation of preglomerular vascular smooth muscle cells and glomerular mesangial cells via A<sub>2B</sub> receptors. *J Pharmacol Exp Ther*. 2011;337:444–450. doi: 10.1124/jpet.110.178137.
  37. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. *Pharmacol Rev*. 2011;63:1–34. doi: 10.1124/pr.110.003285.
  38. Wu YJ, Bond M, Sala-Newby GB, Newby AC. Altered S-phase kinase-associated protein-2 levels are a major mediator of cyclic nucleotide-induced inhibition of vascular smooth muscle cell proliferation. *Circ Res*. 2006;98:1141–1150. doi: 10.1161/01.RES.0000219905.16312.28.
  39. Wu YJ, Sala-Newby GB, Shu KT, Yeh HI, Nakayama KI, Nakayama K, Newby AC, Bond M. S-phase kinase-associated protein-2 (Skp2) promotes vascular smooth muscle cell proliferation and neointima formation in vivo. *J Vasc Surg*. 2009;50:1135–1142. doi: 10.1016/j.jvs.2009.07.066.
  40. Li Y, Takahashi M, Stork PJ. Ras-mutant cancer cells display B-Raf binding to Ras that activates extracellular signal-regulated kinase and is inhibited by protein kinase A phosphorylation. *J Biol Chem*. 2013;288:27646–27657. doi: 10.1074/jbc.M113.463067.
  41. Begum N, Hockman S, Manganiello VC. Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins. *J Biol Chem*. 2011;286:26238–26249. doi: 10.1074/jbc.M110.214155.
  42. Madhetti S, Schneble N, König C, Hirsch E, Schulz S, Müller JP, Wetzker R. PI3Kγ integrates cAMP and Akt signalling of the μ-opioid receptor. *Br J Pharmacol*. 2014;171:3328–3337. doi: 10.1111/bph.12698.
  43. Dubey RK, Jackson EK, Gillespie DG, Zacharia LC, Imthurn B, Keller PJ. Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity. *Arterioscler Thromb Vasc Biol*. 2000;20:964–972.
  44. Barchiesi F, Jackson EK, Imthurn B, Fingerle J, Gillespie DG, Dubey RK. Differential regulation of estrogen receptor subtypes α and β in human aortic smooth muscle cells by oligonucleotides and estradiol. *J Clin Endocrinol Metab*. 2004;89:2373–2381. doi: 10.1210/jc.2003-030821.
  45. Barchiesi F, Jackson EK, Fingerle J, Gillespie DG, Odermatt B, Dubey RK. 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. *Circ Res*. 2006;99:266–274. doi: 10.1161/01.RES.0000233318.85181.2e.
  46. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. *Lab Invest*. 1983;49:327–333.
  47. Reis ED, Roqué M, Cordon-Cardo C, Drobniak M, Fuster V, Badimon JJ. Apoptosis, proliferation, and p27 expression during vessel wall healing: time course study in a mouse model of transluminal femoral artery injury. *J Vasc Surg*. 2000;32:1022–1029. doi: 10.1067/mva.2000.109763.
  48. Hay C, Micko C, Prescott MF, Liau G, Robinson K, De Leon H. Differential cell cycle progression patterns of infiltrating leukocytes and resident cells after balloon injury of the rat carotid artery. *Arterioscler Thromb Vasc Biol*. 2001;21:1948–1954.
  49. Stewart SA, Kothapalli D, Yung Y, Assoian RK. Antimitogenesis linked to regulation of Skp2 gene expression. *J Biol Chem*. 2004;279:29109–29113. doi: 10.1074/jbc.M404271200.
  50. Feoktistov I, Biaggioni I. Adenosine A<sub>2B</sub> receptors. *Pharmacol Rev*. 1997;49:381–402.
  51. Indolfi C, Avvedimento EV, Di Lorenzo E, Esposito G, Rapacciuolo A, Giuliano P, Grieco D, Cavuto L, Stingone AM, Ciullo I, Condorelli G, Chiariello M. Activation of cAMP-PKA signaling *in vivo* inhibits smooth muscle cell proliferation induced by vascular injury. *Nat Med*. 1997;3:775–779.
  52. Seivour EG, Sehgal V, Lu Y, et al. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. *Oncogene*. 2015;2:469.

53. Santulli G, Wronska A, Uryu K, Diacovo TG, Gao M, Marx SO, Kitajewski J, Chilton JM, Akat KM, Tuschl T, Marks AR, Totary-Jain H. A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. *J Clin Invest*. 2014;124:4102–4114. doi: 10.1172/JCI76069.
54. Yang D, Koupenova M, McCrann DJ, Kopeikina KJ, Kagan HM, Schreiber BM, Ravid K. The A<sub>2b</sub> adenosine receptor protects against vascular injury. *Proc Natl Acad Sci U S A*. 2008;105:792–796. doi: 10.1073/pnas.0705563105.
55. Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M, Jones MR, St Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, Gavras H, Wagner DD, Ravid K. The A<sub>2b</sub> adenosine receptor protects against inflammation and excessive vascular adhesion. *J Clin Invest*. 2006;116:1913–1923. doi: 10.1172/JCI27933.
56. Koupenova M, Johnston-Cox H, Vezeridis A, Gavras H, Yang D, Zannis V, Ravid K. A<sub>2b</sub> adenosine receptor regulates hyperlipidemia and atherosclerosis. *Circulation*. 2012;125:354–363. doi: 10.1161/CIRCULATIONAHA.111.057596.
57. Ryzhov S, Goldstein AE, Biaggioni I, Feoktistov I. Cross-talk between G<sub>s</sub>- and G<sub>i</sub>-coupled pathways in regulation of interleukin-4 by A<sub>2b</sub> adenosine receptors in human mast cells. *Mol Pharmacol*. 2006;70:727–735. doi: 10.1124/mol.106.022780.
58. Cohen MV, Yang X, Downey JM. A<sub>2b</sub> adenosine receptors can change their spots. *Br J Pharmacol*. 2010;159:1595–1597. doi: 10.1111/j.1476-5381.2010.00668.x.
59. Cheng D, Zhu X, Gillespie DG, Jackson EK. Role of RACK1 in the differential proliferative effects of neuropeptide Y<sub>1-36</sub> and peptide YY<sub>1-36</sub> in SHR vs. WKY preglomerular vascular smooth muscle cells. *Am J Physiol Renal Physiol*. 2013;304:F770–F780. doi: 10.1152/ajprenal.00646.2012.
60. Shen J, Halenda SP, Sturek M, Wilden PA. Cell-signaling evidence for adenosine stimulation of coronary smooth muscle proliferation via the A<sub>1</sub> adenosine receptor. *Circ Res*. 2005;97:574–582. doi: 10.1161/01.RES.0000181159.83588.4b.
61. Shen J, Halenda SP, Sturek M, Wilden PA. Novel mitogenic effect of adenosine on coronary artery smooth muscle cells: role for the A<sub>1</sub> adenosine receptor. *Circ Res*. 2005;96:982–990. doi: 10.1161/01.RES.0000165800.81876.52.
62. Dai Y, Zhang W, Wen J, Zhang Y, Kellems RE, Xia Y. A<sub>2b</sub> adenosine receptor-mediated induction of IL-6 promotes CKD. *J Am Soc Nephrol*. 2011;22:890–901. doi: 10.1681/ASN.2010080890.
63. Karmouty-Quintana H, Philip K, Acero LF, et al. Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension. *FASEB J*. 2015;29:50–60. doi: 10.1096/fj.14-260182.

## Novelty and Significance

### What Is New?

- Endogenous and exogenous adenosine inhibits human coronary artery smooth muscle cell (HCASMC) proliferation and migration.
- The inhibitory effect of adenosine on HCASMC proliferation is mediated via A<sub>2b</sub> receptor activation of adenylyl cyclase, leading to the accumulation of cAMP and stimulation of protein kinase A.
- Protein kinase A inhibits HCASMC proliferation by blocking multiple signaling pathways (ERK1/2, Akt, and Skp2) that converge at cyclin D—the net result being a reduced expression and function of this key G1 cyclin that governs cell-cycle progression.
- Adenosine analogues can be applied peri-arterially in a slow release gel formulation to inhibit vascular injury–induced neointimal hyperplasia.
- If the A<sub>2b</sub> receptor system becomes deficient, A<sub>1</sub> receptor signaling becomes dominant and increases HCASMC proliferation.

### What Is Relevant?

- A<sub>2b</sub> receptor activation is a straightforward approach to inhibit HCASMC proliferation and migration.

- It is possible to apply A<sub>2b</sub> receptor agonists peri-arterially to block neointimal hyperplasia while obviating unwanted systemic adverse effects.
- The ratio of A<sub>1</sub> to A<sub>2b</sub> receptor expression may determine risk of coronary artery disease and the response to adenosine receptor agonists.
- Other agents that modulate the actions of ERK1/2, Akt, Skp2, p27<sup>Kip1</sup>, cyclin D, Rb, or cyclin A may have therapeutic efficacy in cardiovascular medicine.

### Summary

The adenosine/A<sub>2b</sub> receptor/cAMP/protein kinase A axis inhibits HCASMC proliferation by blocking multiple signaling pathways (ERK1/2, Akt, and Skp2) that converge at cyclin D; the net result being a reduced expression and function of this key G1 cyclin that governs cell-cycle progression.